Skip to main content


CASPIAN is an open-label, phase III trial investigating the addition of the PD-L1 inhibitor durvalumab, either with or without the CTLA-4 inhibitor tremelimumab, to a chemotherapy backbone comprising etoposide plus carboplatin or cisplatin, in patients with previously untreated extensive-stage small-cell lung cancer (ES-SCLC).

The PD-L1 inhibitor has previously been approved for the treatment of stage III non-small-cell lung cancer in USA, Europe, and other countries, following the positive results of the PACIFIC trial.

Phase III trial results

Adding durvalumab to first-line chemotherapy has been shown to significantly improve the overall survival of patients with ES-SCLC.

Advisory Board member Ross Camidge discusses the implications of this trial in his round-up of key data presented at WCLC 2019 (1:51):

The overall survival results of the durvalumab plus chemotherapy arm of CASPIAN were presented at WCLC 2019:

Title: Overall survival with durvalumab plus etoposide-platinum in first-line extensive-stage SCLC: Results from the CASPIAN study
Presenter: Luis Paz-Ares, Hospital 12 de Octubre, Madrid, Spain
Monday, September 9: 09:38–09:48 (Abstract PL02.11)

Back to the WCLC 2019 conference hub